GleamWall
中文EN

OVID Ovid Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1636651 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-78.0%
TTM net income YoY-18.7%
TTM EPS YoY—
Revenue 3-yr CAGR69.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,700.3%
Net margin-2,971.3%
FCF margin—
EBITDA margin-4,694.6%

Returns

ROE-35.4%
ROA-30.1%
ROIC (approx.)-52.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets10.6%
Debt / equity0.00x
Current ratio11.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.34x
Accruals ratio10.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$733,000$0$718,000$132,000$6.27M$130,000$76,000
R&D expense$15.70M$9.96M$11.18M$6.59M$5.87M$6.46M$6.66M$5.92M
SG&A expense$6.67M$6.47M$6.67M$6.42M$6.79M$4.88M$6.02M$4.88M
Operating income-$22.36M-$15.70M-$17.85M-$12.29M-$12.52M-$5.07M-$12.55M-$10.72M
Pretax income-$20.78M-$15.01M-$16.99M$9.66M-$12.16M-$4.68M-$10.23M-$9.25M
Income tax$0$0$0$0$0$0$0$0
Net income-$20.78M-$15.01M-$16.99M$9.66M-$12.16M-$4.68M-$10.23M-$9.25M
EBITDA-$22.35M-$15.68M-$17.81M-$12.28M-$12.51M-$5.01M-$12.41M-$10.56M
EPS (diluted)————————
Balance sheet
Cash & equivalents$13.81M$11.33M$94.06M$13.15M$22.54M$30.35M$23.07M$28.23M
Short-term investments$122.79M$105.89M$61.46M$56.48M$4.99M$9.93M$21.86M$26.77M
Current assets$141.96M$123.62M$160.15M$74.37M$28.82M$42.09M$45.92M$55.94M
PP&E, net$186,000$201,000$217,000$252,000$269,000$285,000$346,000$433,000
Intangibles$0$0$0$0$0$0$38,000$100,000
Total assets$222.24M$231.97M$225.63M$150.93M$63.85M$77.43M$81.65M$92.17M
Current liabilities$11.86M$9.98M$15.75M$8.29M$6.80M$8.92M$9.31M$10.52M
Total liabilities$23.57M$22.08M$27.36M$20.27M$19.15M$21.64M$22.38M$23.94M
Shareholders' equity$198.67M$209.89M$198.27M$130.66M$44.70M$55.79M$59.28M$68.23M
Shares outstanding188.72M184.76M167.27M130.18M71.15M71.11M71.11M71.01M
Cash flow statement
Operating cash flow-$15.88M-$17.59M-$13.90M-$10.41M-$12.87M-$4.77M-$10.28M-$10.01M
Capital expenditure———$0$0$0$0$22,000
Free cash flow———-$10.41M-$12.87M-$4.77M-$10.28M-$10.03M
Investing cash flow$11.15M-$86.74M$5.95M-$72.06M$5.05M$12.05M$5.10M$21.29M
Financing cash flow$7.28M$21.60M$88.98M$75.18M$15,000$0$13,000$0
Depreciation & amortization$15,000$16,000$35,000$17,000$17,000$61,000$141,000$160,000
Stock-based compensation$1.28M$1.43M$1.05M$1.20M$1.11M$1.22M$1.28M$1.26M

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.